NCT05146921

Gut Health and Probiotics in Parkinson's (SymPD)

Status unknown NA Last updated 2 September 2022

What this trial tests

NA trial testing Multi-strain probiotic in Parkinson Disease in 60 participants. Status unknown.

Timeline

4 July 2019

Primary endpoint
15 July 2023

15 July 2023

Quick facts

Lead sponsor	King's College Hospital NHS Trust
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	60
Start date	4 July 2019
Primary completion	15 July 2023
Estimated completion	15 July 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

• Multi-strain probiotic
• Placebo

Conditions studied

• Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

King's College Hospital NHS Trust

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current literature suggests that the gut microbiota is altered in patients with Parkinson's disease (PD) and might play a role in the clinical presentation and pathogenesis of this condition. The latter has driven the interest in investigating the use of gut microbiota-modulating interventions, such as probiotics, as possible novel therapeutic strategies for PD. Symprove is a food supplement working as an oral active probiotic which unlike many commercially available probiotics can reach the intestine and has been shown to be beneficial for gut health in gastrointestinal disorders.To date, no research has explored the possible effects of the intake of Symprove in PD. This is an exploratory study with a randomised, double-blind, placebo-controlled design investigating the effects of a 12-week probiotic intervention (Symprove) on gut and general health in 60 patients with PD and constipation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases.
   Loh JS, Mak WQ, Tan LKS, Ng CX, et al · · 2024 · cited 631× · PMID 38360862 · DOI 10.1038/s41392-024-01743-1
2. Inflammatory Animal Models of Parkinson's Disease.
   García-Revilla J, Herrera AJ, de Pablos RM, Venero JL. · · 2022 · cited 22× · PMID 35662128 · DOI 10.3233/jpd-213138
3. The Role of Diet in Parkinson's Disease.
   Tosefsky KN, Zhu J, Wang YN, Lam JST, et al · · 2024 · cited 21× · PMID 38251061 · DOI 10.3233/jpd-230264
4. Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer's and Parkinson's disease.
   Denman CR, Park SM, Jo J. · · 2023 · cited 20× · PMID 38075261 · DOI 10.3389/fnins.2023.1268419
5. Microbiome-based therapeutics for Parkinson's disease.
   Hamilton AM, Krout IN, White AC, Sampson TR. · · 2024 · cited 16× · PMID 39393983 · DOI 10.1016/j.neurot.2024.e00462
6. Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson's disease model.
   Sancandi M, De Caro C, Cypaite N, Marascio N, et al · · 2022 · cited 14× · PMID 36742204 · DOI 10.3389/fnagi.2022.986127
7. New Pieces for an Old Puzzle: Approaching Parkinson's Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics.
   Ortega Moreno L, Bagues A, Martínez V, Abalo R. · · 2023 · cited 8× · PMID 37375679 · DOI 10.3390/nu15122775
8. From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment?
   Vilela C, Araújo B, Soares-Guedes C, Caridade-Silva R, et al · · 2024 · cited 7× · PMID 38727306 · DOI 10.3390/cells13090770